Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 1/2005

01.01.2005 | Article

Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain

verfasst von: J. Pemán, E. Cantón, M. Gobernado, and the Spanish ECMM Working Group on Candidaemia

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

This study, included in the prospective survey of candidaemia in Europe supported by the European Confederation of Medical Mycology, presents the epidemiological and antifungal susceptibility results of 290 cases of candidaemia (80 in children <15 years old) reported from September 1997 to August 1999 by 19 Spanish hospitals. Presence of an intravenous catheter and previous antibiotic therapy were the most frequent risk factors. The percentages of the four most common species isolated (adults/children) were as follows: Candida albicans (46/36.2), C. parapsilosis (21.9/50), C. tropicalis (12.8/3.75), and C. glabrata (10.1/5). As initial therapy, fluconazole was preferred in adults (54%) and liposomal amphotericin B in children (58%). The 30-day mortality rate was 40.6%, and the species most frequently associated with a fatal outcome was C. krusei (60%). The rates of susceptibility to antifungal agents were as follows: amphotericin B, 91%; flucytosine, 99%; fluconazole, 93.6%; itraconazole, 87.4%; and voriconazole, 92%. These results provide baseline data for future epidemiological and susceptibility studies and for evaluating the impact of new antifungal agents on the distribution of species and the mortality rates associated with candidaemia in Spain.
Literatur
1.
Zurück zum Zitat Beck-Sagué CM, Jarvis WR, and the National Nosocomial Infections Surveillance System (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J lnfect Dis 167:1247–1251 Beck-Sagué CM, Jarvis WR, and the National Nosocomial Infections Surveillance System (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J lnfect Dis 167:1247–1251
2.
Zurück zum Zitat Abi-Said D, Anaissie E, Uzun O, Raad L, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128PubMed Abi-Said D, Anaissie E, Uzun O, Raad L, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128PubMed
3.
Zurück zum Zitat Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244PubMed Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244PubMed
4.
Zurück zum Zitat Wey SB, Mori M, Pfaller MA et al (1988) Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645PubMed Wey SB, Mori M, Pfaller MA et al (1988) Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645PubMed
5.
Zurück zum Zitat Wenzel RP, Edmond MB (2001) The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 7:174–177PubMed Wenzel RP, Edmond MB (2001) The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 7:174–177PubMed
6.
Zurück zum Zitat Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW (2000) Candida infections: outcome and attributable ICU cost in critically ill patients. J Intensive Care Med 15:255–261 Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW (2000) Candida infections: outcome and attributable ICU cost in critically ill patients. J Intensive Care Med 15:255–261
7.
Zurück zum Zitat Pfaller MA, Diekema DJ (2002) Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40:3551–3557PubMed Pfaller MA, Diekema DJ (2002) Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40:3551–3557PubMed
8.
Zurück zum Zitat Collin B, Clancy CJ, Nguyen MH (1999) Antifungal resistance in non-albicans Candida species. Drug Resistance Updates 3:9–14 Collin B, Clancy CJ, Nguyen MH (1999) Antifungal resistance in non-albicans Candida species. Drug Resistance Updates 3:9–14
9.
Zurück zum Zitat St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G (2001) Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 39:949–953PubMed St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G (2001) Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 39:949–953PubMed
10.
Zurück zum Zitat Sandven P (2000) Epidemiology of candidemia. Rev Iberoam Micol 17:73–81 Sandven P (2000) Epidemiology of candidemia. Rev Iberoam Micol 17:73–81
11.
Zurück zum Zitat Viscoli C, Girmenia C, Marinus A, Viscoli Collette L, Martino P, Vandercam B, Doyen C, Lebeau B et al (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin lnfect Dis 28:1071–1079 Viscoli C, Girmenia C, Marinus A, Viscoli Collette L, Martino P, Vandercam B, Doyen C, Lebeau B et al (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin lnfect Dis 28:1071–1079
12.
Zurück zum Zitat Launay O, Lortholary O, Bouges-Michel C, Jarrousse B, Bentata M, Guillevin L (1998) Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 26:1134–1141PubMed Launay O, Lortholary O, Bouges-Michel C, Jarrousse B, Bentata M, Guillevin L (1998) Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 26:1134–1141PubMed
13.
Zurück zum Zitat Tumbarello M, Tacconelli E, De Gaetano Donati K, Morace G, Fadda G, Cauda R (1999) Candidemia in HIV-infected subjects. Eur J Clin Microbiol lnfect Dis 18:478–483 Tumbarello M, Tacconelli E, De Gaetano Donati K, Morace G, Fadda G, Cauda R (1999) Candidemia in HIV-infected subjects. Eur J Clin Microbiol lnfect Dis 18:478–483
14.
Zurück zum Zitat National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. NCCLS, Wayne, PA National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. NCCLS, Wayne, PA
15.
Zurück zum Zitat Sabo JA, Abdel-Rahman SM (2000) Voriconazole: a new triazole antifungal. Ann Pharmacother 34:1032–1043 Sabo JA, Abdel-Rahman SM (2000) Voriconazole: a new triazole antifungal. Ann Pharmacother 34:1032–1043
16.
Zurück zum Zitat Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC et al (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643–658CrossRefPubMed Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC et al (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643–658CrossRefPubMed
18.
Zurück zum Zitat Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, Whimbey E, Hachem R et al (2000) Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 160:2659–2664PubMed Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, Whimbey E, Hachem R et al (2000) Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 160:2659–2664PubMed
19.
Zurück zum Zitat Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yo VL (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617–623PubMed Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yo VL (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617–623PubMed
20.
Zurück zum Zitat Yamamura DL, Rotstein C, Nicolle LE, Ioannou S (1999) Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992–1994. Can Med Assoc J 160:493–499 Yamamura DL, Rotstein C, Nicolle LE, Ioannou S (1999) Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992–1994. Can Med Assoc J 160:493–499
21.
Zurück zum Zitat Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414–421PubMed Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414–421PubMed
22.
Zurück zum Zitat Pemán J, Cantón E, Orero A, Viudes A, Frasquet J, Gobernado M (2002) Epidemiology of candidemia in Spain—multicenter study. Rev Iberoam Micol 19:30–35PubMed Pemán J, Cantón E, Orero A, Viudes A, Frasquet J, Gobernado M (2002) Epidemiology of candidemia in Spain—multicenter study. Rev Iberoam Micol 19:30–35PubMed
23.
Zurück zum Zitat Tortorano AM, Pemán J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Cantón E, Zimmermann K, Seaton S, Grillot R, and the ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317–322PubMed Tortorano AM, Pemán J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Cantón E, Zimmermann K, Seaton S, Grillot R, and the ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317–322PubMed
24.
Zurück zum Zitat Viudes A, Pemán J, Cantón E, Úbeda P, López-Ribot JL, Gobernado M (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21:767–774PubMed Viudes A, Pemán J, Cantón E, Úbeda P, López-Ribot JL, Gobernado M (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21:767–774PubMed
25.
Zurück zum Zitat Sota M, Ezpeleta C, Cisterna R (1999) Description of 165 episodes of fungemia: a multicenter study. Rev Iberoam Micol 16:30–35 Sota M, Ezpeleta C, Cisterna R (1999) Description of 165 episodes of fungemia: a multicenter study. Rev Iberoam Micol 16:30–35
26.
Zurück zum Zitat Ainscough S, Barnes R, Gant V, Gransden WR (2000) Bloodstream infections due to Candida species in England and Wales: data from the ECMM epidemiological survey of candidaemia in Europe. Rev Iberoam Micol 17(Suppl 1):S143 Ainscough S, Barnes R, Gant V, Gransden WR (2000) Bloodstream infections due to Candida species in England and Wales: data from the ECMM epidemiological survey of candidaemia in Europe. Rev Iberoam Micol 17(Suppl 1):S143
27.
Zurück zum Zitat Bernhardt H, Zimmermann K, Sissolak D, Schutt-Gerowitt H (2000) Epidemiological survey on candidemia in Europe: results of Germany and Austria. Rev Iberoam Micol 17(Suppl 1):S146 Bernhardt H, Zimmermann K, Sissolak D, Schutt-Gerowitt H (2000) Epidemiological survey on candidemia in Europe: results of Germany and Austria. Rev Iberoam Micol 17(Suppl 1):S146
28.
Zurück zum Zitat Grillot R, Faure O, Fruit J, Sendid B (2000) Working group: ECMM candidemia. ECMM prospective epidemiological survey of candidemia in Europe: report from France. Rev Iberoam Micol 17(Suppl 1):S144 Grillot R, Faure O, Fruit J, Sendid B (2000) Working group: ECMM candidemia. ECMM prospective epidemiological survey of candidemia in Europe: report from France. Rev Iberoam Micol 17(Suppl 1):S144
29.
Zurück zum Zitat Klingspor L, Tornquist E, Johansson A, Petrini B (2000) ECMM’s survey of candidemia in Europe: report from Sweden. Rev Iberoam Micol 17(Suppl 1):S147 Klingspor L, Tornquist E, Johansson A, Petrini B (2000) ECMM’s survey of candidemia in Europe: report from Sweden. Rev Iberoam Micol 17(Suppl 1):S147
30.
Zurück zum Zitat Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A, and the FIMUA Candidemia Study Group (2002) European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51:297–304PubMed Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A, and the FIMUA Candidemia Study Group (2002) European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51:297–304PubMed
31.
Zurück zum Zitat Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A (1988) Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 26:429–432PubMed Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A (1988) Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 26:429–432PubMed
32.
Zurück zum Zitat Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman OL, Wiblin RT, Wenzel RP, and the NEMIS Study Group (2001) Risk factors for Candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177–186PubMed Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman OL, Wiblin RT, Wenzel RP, and the NEMIS Study Group (2001) Risk factors for Candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177–186PubMed
33.
Zurück zum Zitat Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692–1696PubMed Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692–1696PubMed
34.
Zurück zum Zitat Krcmery V Jr, Kovacicova G (2000) Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 36:7–11PubMed Krcmery V Jr, Kovacicova G (2000) Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 36:7–11PubMed
35.
Zurück zum Zitat Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RI (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 44:747–751PubMed Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RI (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 44:747–751PubMed
36.
Zurück zum Zitat Gómez J, Baños V, Simarro E, Ruiz J, Requena L, Pérez J, Canteras M, Valdés M (2001) Nosocomial fungemias in a general hospital. Epidemiology and prognostic factors. Prospective study 1993–1998. Enferm Infecc Microbiol Clin 19:304–307PubMed Gómez J, Baños V, Simarro E, Ruiz J, Requena L, Pérez J, Canteras M, Valdés M (2001) Nosocomial fungemias in a general hospital. Epidemiology and prognostic factors. Prospective study 1993–1998. Enferm Infecc Microbiol Clin 19:304–307PubMed
37.
Zurück zum Zitat Rodríguez-Tudela JL, Cuenca-Estrella M (1999) A multicenter study on fungemia caused by yeasts in Spain (April–June 1997). A work group to study fungemia. Rev Clin Esp 199:356–361PubMed Rodríguez-Tudela JL, Cuenca-Estrella M (1999) A multicenter study on fungemia caused by yeasts in Spain (April–June 1997). A work group to study fungemia. Rev Clin Esp 199:356–361PubMed
38.
Zurück zum Zitat Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M (1998) Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 36:3455–3459PubMed Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M (1998) Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 36:3455–3459PubMed
39.
Zurück zum Zitat Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R (2000) Epidemiology of candidemia, a nationwide survey in Israel. Infection 28:26–29PubMed Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R (2000) Epidemiology of candidemia, a nationwide survey in Israel. Infection 28:26–29PubMed
40.
Zurück zum Zitat Oude Lashof AM, Donnelly JP, Meis JF, van derMeer JW, Kullberg BJ (2003) Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 22:43–48PubMed Oude Lashof AM, Donnelly JP, Meis JF, van derMeer JW, Kullberg BJ (2003) Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 22:43–48PubMed
41.
Zurück zum Zitat Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243–260CrossRefPubMed Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243–260CrossRefPubMed
42.
Zurück zum Zitat Jarque I, Saavedra S, Martín G, Pemán J, Pérez Belles C, Sanz MA (2000) Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole. Haematologica 85:441–443PubMed Jarque I, Saavedra S, Martín G, Pemán J, Pérez Belles C, Sanz MA (2000) Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole. Haematologica 85:441–443PubMed
43.
Zurück zum Zitat Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154PubMed Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149–3154PubMed
44.
Zurück zum Zitat Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL (2002) Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999. J Antimicrob Chemother 49:981–987PubMed Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL (2002) Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999. J Antimicrob Chemother 49:981–987PubMed
45.
Zurück zum Zitat Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA, and the FIMUA-ECMM Candidaemia Study Group (2003) The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 52:679–682PubMed Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA, and the FIMUA-ECMM Candidaemia Study Group (2003) The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 52:679–682PubMed
46.
Zurück zum Zitat Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J et al (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42:1519–1527PubMed Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J et al (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42:1519–1527PubMed
47.
Zurück zum Zitat Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46:1723–1727CrossRefPubMed Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46:1723–1727CrossRefPubMed
48.
Zurück zum Zitat Marco F, Danes C, Almela M, Jurado A, Mensa J, de la Bellacasa JP, Espasa M, Martinez JA et al (2003) Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996–2001). Diagn Microbiol Infect Dis 46:259–264PubMed Marco F, Danes C, Almela M, Jurado A, Mensa J, de la Bellacasa JP, Espasa M, Martinez JA et al (2003) Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996–2001). Diagn Microbiol Infect Dis 46:259–264PubMed
49.
Zurück zum Zitat Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46:3518–3521PubMed Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46:3518–3521PubMed
50.
Zurück zum Zitat Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A (2003) Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45:203–206PubMed Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A (2003) Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45:203–206PubMed
Metadaten
Titel
Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain
verfasst von
J. Pemán
E. Cantón
M. Gobernado
and the Spanish ECMM Working Group on Candidaemia
Publikationsdatum
01.01.2005
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 1/2005
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1267-5

Weitere Artikel der Ausgabe 1/2005

European Journal of Clinical Microbiology & Infectious Diseases 1/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.